First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber
Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.
Related Articles
How we improved the treatment of Hodgkin lymphoma – The Cancer Letter
Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately…
Going straight to the source in defense against infant RSV
Fred Hutch Cancer Center scientists developed an engineered antibody that may be able to target immune cells capable of producing a protective response against RSV.…
FDA approves revumenib for certain patients with advanced acute leukemia
The FDA approved revumenib for the treatment of certain patients with advanced acute leukemia.The indication applies to use of the agent by adults or by…
Program
Program for AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer
Clive Peedell (@drpeedell.bsky.social)
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
Finding the right friends: Stromal composition influences TLS formation in ovarian cancer
In this issue of Cancer Cell, MacFawn et al. reveal that tertiary lymphoid structures (TLSs) in high-grade serous ovarian cancer (HGSOC) vary significantly by anatomical site.…
Padeliporfin VTP Maintains Robust Responses and is Safe in Low-Grade Upper-Tract Urothelial Cancer
Updated interim data show high complete responses and tolerability with padeliporfin VTP in low-grade upper tract urothelial cancer.
NewsDetails
Rachel Darwin, Senior Manager, Public Relations The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology…
Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC
The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.